Spots Global Cancer Trial Database for recurrent nasopharynx carcinoma

Every month we try and update this database with for recurrent nasopharynx carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery	NCT02538510	Head and Neck S... Recurrent Nasal... Recurrent Nasop... Recurrent Saliv... Squamous Cell C... Stage III Major... Stage III Nasal... Stage III Nasop... Stage IV Nasoph... Stage IVA Major... Stage IVA Nasal... Stage IVB Major... Stage IVB Nasal... Stage IVC Major... Stage IVC Nasal...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	University of Washington
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	NCT03074513	Appendix Adenoc... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Neuroendocrine ... Pancreatic Neur... Recurrent Merke... Recurrent Nasop... Recurrent Perit... Recurrent Pleur... Stage III Merke... Stage III Nasop... Stage III Pleur... Stage IV Merkel... Stage IV Nasoph... Stage IV Pleura... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop... Vaginal Squamou...	Atezolizumab Bevacizumab Laboratory Biom... Pharmacological...	18 Years -	M.D. Anderson Cancer Center
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer	NCT02706691	FGFR Gene Ampli... FGFR1 Gene Ampl... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR3 Gene Muta... Head and Neck S... Human Papilloma... Recurrent Head ... Recurrent Nasop... Recurrent Oroph...	BGJ398	18 Years -	University of Chicago
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer	NCT02339558	Nasopharyngeal ... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop...	Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer	NCT02339558	Nasopharyngeal ... Recurrent Nasop... Stage III Nasop... Stage IV Nasoph... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop...	Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma	NCT02137096	Recurrent Nasop...	Etoposide phosp... Carboplatin Ifosfamide Autologous Stem...	2 Years - 30 Years	University of Florida
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	NCT03074513	Appendix Adenoc... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Neuroendocrine ... Pancreatic Neur... Recurrent Merke... Recurrent Nasop... Recurrent Perit... Recurrent Pleur... Stage III Merke... Stage III Nasop... Stage III Pleur... Stage IV Merkel... Stage IV Nasoph... Stage IV Pleura... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop... Vaginal Squamou...	Atezolizumab Bevacizumab Laboratory Biom... Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma	NCT02137096	Recurrent Nasop...	Etoposide phosp... Carboplatin Ifosfamide Autologous Stem...	2 Years - 30 Years	University of Florida

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: